4 - Maxpro Capital Acquisition Corp. (0001874259) (Issuer)

4 - Maxpro Capital Acquisition Corp. (0001874259) (Issuer)

4 - Maxpro Capital Acquisition Corp. (0001874259) (Issuer)

4 - Maxpro Capital Acquisition Corp. (0001874259) (Issuer)

4 - Maxpro Capital Acquisition Corp. (0001874259) (Issuer)

4 - Maxpro Capital Acquisition Corp. (0001874259) (Issuer)

4 - Maxpro Capital Acquisition Corp. (0001874259) (Issuer)

SC 13G/A - Maxpro Capital Acquisition Corp. (0001874259) (Subject)

SC 13G/A - Maxpro Capital Acquisition Corp. (0001874259) (Subject)

SC 13G/A - Maxpro Capital Acquisition Corp. (0001874259) (Subject)

SC 13G/A - Maxpro Capital Acquisition Corp. (0001874259) (Subject)

SC 13G - Maxpro Capital Acquisition Corp. (0001874259) (Subject)

SC 13G - Maxpro Capital Acquisition Corp. (0001874259) (Subject)

SC 13G - Maxpro Capital Acquisition Corp. (0001874259) (Subject)

SC 13G/A - Maxpro Capital Acquisition Corp. (0001874259) (Subject)

SC 13G - Maxpro Capital Acquisition Corp. (0001874259) (Subject)

SC 13G/A - Maxpro Capital Acquisition Corp. (0001874259) (Subject)

15-12G - Maxpro Capital Acquisition Corp. (0001874259) (Filer)

10-K - Maxpro Capital Acquisition Corp. (0001874259) (Filer)

8-K - Maxpro Capital Acquisition Corp. (0001874259) (Filer)

25-NSE - Maxpro Capital Acquisition Corp. (0001874259) (Subject)

8-K - Maxpro Capital Acquisition Corp. (0001874259) (Filer)

8-K - Maxpro Capital Acquisition Corp. (0001874259) (Filer)

425 - Maxpro Capital Acquisition Corp. (0001874259) (Subject)

8-K - Maxpro Capital Acquisition Corp. (0001874259) (Filer)

425 - Maxpro Capital Acquisition Corp. (0001874259) (Subject)

8-K - Maxpro Capital Acquisition Corp. (0001874259) (Filer)

FOSTER CITY, Calif., March 30, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. ("Apollomics" or the "Company"), a clinical-stage biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced the completion of its business combination (the "Business Combination") with Maxpro Capital Acquisition Corp. (("Maxpro", NASDAQ:JMAC). Apollomics' Class A ordinary shares and public warrants are expected to commence trading today, March 30, 2023, on the Nasdaq Capital Market (Nasdaq) under the symbols "APLM" and "APLMW," respectively. The Business Combination, which was approved by Maxpro's shareholders on March 20, 2023,

Taipei City, Jan. 13, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Maxpro Capital Acquisition Corp. (NASDAQ:JMAC) (the "Company") announced today that its sponsor, MP One Investment LLC (the "Sponsor") and Apollomics Inc. ("Apollomics"), deposited additional payments in the aggregate amount of $1,035,000 (representing $0.10 per public share) (the "Extension Payment") into the Company's trust account for its public stockholders. This deposit enables the Company to extend the date by which the Company has to complete its initial business combination from January 13, 2023 to April 13, 2023 (the "Extension"). The Extension is the second of two three-month extensions permitted under the Company

TAIPEI CITY, Jan. 10, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Maxpro Capital Acquisition Corp. (NASDAQ:JMAC) (the "Company"), announced today that its sponsor, MP One Investment LLC (the "Sponsor"), has requested that the Company extend the date by which the Company has to consummate a business combination from January 13, 2023 to April 13, 2023 (the "Extension"). The Extension is the second of two three-month extensions permitted under the Company's governing documents. In connection with the Extension, the Sponsor and Apollomics Inc. ("Apollomics") have notified the Company that they intend to bear the cost of the Extension in the aggregate amount of $1,035,000 (representing $0.10 pe

FOSTER CITY, Calif., Nov. 15, 2022 (GLOBE NEWSWIRE) -- Apollomics Inc. (NASDAQ:JMAC), an innovative biopharmaceutical company committed to the discovery and development of mono- and combination-oncology therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to vebreltinib (APL-101) for the treatment of non-small cell lung cancer (NSCLC) with MET genomic tumor aberrations. The FDA granted the Orphan Drug Designation in August. "While NSCLC is the most common type of lung cancer, a subset of patients will have MET genomic dysregulations in their tumors which make them more resistant to treatment, presenting an unmet medical need," sai

TAIPEI CITY, Oct. 14, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Maxpro Capital Acquisition Corp. (NASDAQ:JMAC) (the "Company") announced today that its sponsor, MP One Investment LLC (the "Sponsor"), deposited an additional payment in the aggregate amount of $1,035,000 (representing $0.10 per public share) (the "Extension Payment") into the Company's trust account for its public stockholders. This deposit enables the Company to extend the date by which the Company has to complete its initial business combination from October 13, 2022 to January 13, 2023 (the "Extension"). The Extension is the first of two three-month extensions permitted under the Company's governing documents. The Exten

Taipei City, Oct. 07, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Maxpro Capital Acquisition Corp. (NASDAQ:JMAC) (the "Company"), announced today that its sponsor, MP One Investment LLC (the "Sponsor"), has requested that the Company extend the date by which the Company has to consummate a business combination from October 13, 2022 to January 13, 2023 (the "Extension"). The Extension is the first of two three-month extensions permitted under the Company's governing documents. In connection with the Extension, the Sponsor has notified the Company that it intends to deposit an aggregate of $1,035,000 (representing $0.10 per public share) into the Company's trust account on or before October

– Transaction values Apollomics at pre-money equity value of $899 million– Apollomics is a late-stage clinical biopharmaceutical company developing innovative product candidates for large, unmet medical needs –Broad pipeline of drug candidates across multiple oncology programs; two lead clinical-stage candidates addressing a combined $11 billion non-small cell lung cancer ("NSCLC") and acute myeloid leukemia ("AML") market opportunity –Transaction proceeds to accelerate development of late-stage clinical programs, vebreltinib (APL-101) and uproleselan (APL-106) FOSTER CITY, Calif. and TAIPEI CITY, Taiwan, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Apollomics Inc. ("Apollomics" or the "Company")

 Apollomics Inc. ("Apollomics" or the "Company"), a clinical-stage biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced the completion of its business combination (the "Business Combination") with Maxpro Capital Acquisition Corp. (("Maxpro", NASDAQ:JMAC). Apollomics' Class A ordinary shares and public warrants are expected to commence trading today, March 30, 2023, on the Nasdaq Capital Market (Nasdaq) under the symbols "APLM" and "APLMW," respectively. The Business Combination, which was approved by Maxpro's shareholders on March 20, 2023, along with a $23.65 million private investment in public

Apollomics' Class A ordinary shares and public warrants are expected to begin trading today on the Nasdaq Capital Market under the ticker symbols 'APLM' and 'APLMW' FOSTER CITY, Calif., Mar 30, 2023 - (ACN Newswire) - Apollomics Inc. ("Apollomics" or the "Company"), a clinical-stage biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced the completion of its business combination (the "Business Combination") with Maxpro Capital Acquisition Corp. (("Maxpro", NASDAQ:JMAC). Apollomics' Class A ordinary shares and public warrants are expected to commence trading today, March 30, 2023, on the Nasdaq Cap

Investors are on the hunt for undervalued, underfollowed and emerging stocks when it comes to spotting opportunities. Retail traders have countless methods at their disposal to uncover new information. For some, this may be overwhelming. Benzinga’s Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks each week that are just under the surface and warrant attention. The index layers editorial commentary to help make sense of why these stocks should be of interest and whether investors and casual readers should watch them. Here is a look at the Benzinga Stock Whisper Index for the week of March 23, 2023. Bank of America Corp (NYSE:BAC): B

Gainers Maxpro Capital Acquisition Corp. (NASDAQ:JMAC) shares jumped 69.6% to $15.01 after dropping 24% on Tuesday. Boxed, Inc. (NYSE:BOXD) gained 56.8% to $0.1882. Boxed recently said it is evaluating potentially filing for relief under the U.S. Bankruptcy Code and other strategic alternatives. Virgin Orbit Holdings, Inc. (NASDAQ:VORB) shares rose 49% to $0.66 following a report suggesting the company is nearing a $200 million investment through a private share placement. The company also said it will initiate an incremental resumption of operations beginning Mar. 23. SCYNEXIS, Inc. (NASDAQ:SCYX) surged 39% to $2.16. 89bio, Inc. (NASDAQ:ETNB) shares jumped 37.5% to $15.06 after the

U.S. stocks traded slightly lower this morning. The Federal Reserve is scheduled to conclude a two-day policy meeting today, with markets expecting a 25 basis-point rate hike. Following the market opening Wednesday, the Dow traded down 0.04% to 32,548.45 while the NASDAQ fell 0.06% to 11,852.83. The S&P 500, also fell, dropping, 0.05% to 4,000.96. Check This Out: These 3 Risk Off Stocks With Over 3% Dividend Yields Are Recommended By Wall Street's Most Accurate Analysts  Leading and Lagging Sectors Information technology shares rose by 0.4% on Wednesday. Meanwhile, top gainers in the sector included Perfect Corp. (NYSE:PERF), up 8%, and DoubleVerify Holdings, Inc. (NYSE:DV), up 2%.

Gainers Virgin Orbit Holdings, Inc. (NASDAQ:VORB) shares rose 81.2% to $0.8032 in pre-market trading. Richard Branson's Virgin Orbit is nearing a deal for a $200 million investment from Texas-based Venture Capital investor Matthew Brown via a private share placement, according to a term sheet. GameStop Corp. (NYSE:GME) climbed 43.7% to $25.37 in pre-market trading after the company reported better-than-expected Q4 results. Diebold Nixdorf, Incorporated (NYSE:DBD) gained 23.1% to $0.9746 in pre-market trading. Diebold Nixdorf confirms closing on $55 million of additional liquidity. Lixiang Education Holding Co., Ltd. (NASDAQ:LXEH) gained 22.1% to $0.88 in pre-market trading after dropp

Gainers U.S. Xpress Enterprises, Inc. (NYSE:USX) shares surged 298% to $5.97 after Knight-Swift Transportation agreed to acquire the company for $6.15 per share. Impac Mortgage Holdings, Inc. (NYSE:IMH) gained 94.8% to $0.39. Impac Mortgage Holdings recently posted a Q4 adjusted loss of $0.35 per share. Cerberus Cyber Sentinel Corporation (NASDAQ:CISO) shares jumped 84.6% to $0.4245. Cerberus Cyber Sentinel said it sees Q4 revenue of $14.7 million and sees FY22 revenue of $46.5 million. Quince Therapeutics, Inc. (NASDAQ:QNCX) gained 74.7% to $1.4708 after Echo Lake Capital offered to acquire the company for $1.60 per share in cash. Pear Therapeutics, Inc.. (NASDAQ:PEAR) climbed 39.3%

Gainers Enzo Biochem, Inc. (NYSE:ENZ) gained 86.5% to $2.22 after the company announced it will sell its clinical laboratory to Labcorp. Histogen Inc. (NASDAQ:HSTO) climbed 60% to $1.39 after the company announced issuance of a US patent covering CTS-2090 methods of use. QualTek Services Inc. (NASDAQ:QTEK) gained 56.4% to $0.4379. QualTek secured new money financing. AirNet Technology Inc. (NASDAQ:ANTE) climbed 38.3% to $1.12. Maxpro Capital Acquisition Corp. (NASDAQ:JMAC) gained 38% to $13.66. Lixiang Education Holding Co., Ltd. (NASDAQ:LXEH) jumped 28% to $1.25. Traeger, Inc. (NYSE:COOK) gained 24% to $3.7415 after the company announced better-than-expected Q4 results. AppTech Pa

-Reuters

-Reuters